Pharmaceuticals Acquisitions in Illinois
-
July 31, 2025
- Buyer
- ESTEVE (Esteve CDMO / Esteve Química)
- Target
- Regis Technologies, Inc.
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Buyout
ESTEVE (Esteve Química / ESTEVE CDMO) has acquired Regis Technologies, a Chicago-based contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and separation products. The acquisition gives ESTEVE a physical U.S. presence, expands its early-stage development and cGMP API manufacturing capabilities, and adds ~70 employees to its US team.
-
- Buyer
- Grünenthal
- Target
- Valinor Pharma
- Seller
- Valinor Pharma
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Buyout
Grünenthal has acquired Chicago-based Valinor Pharma, including global rights to Movantik (naloxegol), in a transaction valued at about $250 million. The deal strengthens Grünenthal's U.S. footprint and adds an established pain-management product to its portfolio after Valinor scaled Movantik sales using Apollo Care's commercial and patient-access solutions.
-
- Buyer
- Formosa Laboratories, Inc.
- Target
- SynChem, Inc.
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Buyout
Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.
-
May 23, 2024
- Buyer
- AbbVie
- Target
- Landos Biopharma, Inc.
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Buyout
AbbVie completed its acquisition of clinical-stage biopharmaceutical company Landos Biopharma for $20.42 per share in cash, plus a contingent value right (CVR) tied to a clinical milestone. The deal adds Landos’ first-in-class investigational asset NX-13 to AbbVie’s immunology pipeline for potential treatment of ulcerative colitis and Crohn’s disease.
-
November 30, 2023
- Buyer
- AbbVie Inc.
- Target
- ImmunoGen, Inc.
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Buyout
AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.
-
March 31, 2021
- Buyer
- SK Capital Partners
- Target
- Woodstock Sterile Solutions
- Seller
- Catalent Pharma Solutions
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Type
- Divestiture
Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.